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Abstract
Tau aggregation is one of the major features in Alzheimer's disease and in several other tauopathies,
including frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), and
progressive supranuclear palsy (PSP). More than 35 mutations in the tau gene have been identified
from FTDP-17 patients. A group of these mutations alters splicing of exon 10, resulting in an
increase in exon 10 inclusion into tau mRNA. Abnormal splicing with inclusion of exon 10 into tau
mRNA has also been observed in PSP and AD patients. These results indicate that abnormal splicing
of exon 10, leading to the production of tau with exon 10, is probably one of the mechanisms by
which tau accumulates and aggregates in tauopathic brains. Therefore, modulation of exon 10
splicing in the tau gene could potentially be targeted to prevent tauopathies. To identify small
molecules or compounds that could potentially be developed into drugs to treat tauopathies, we
established a cell-based high-throughput screening assay. In this review, we will discuss how
realistic, specific biological molecules can be found to regulate exon 10 splicing in the tau gene for
potential treatment of tauopathies.
Alternative splicing of exon 10 in the tau gene
Splicing of pre-mRNA is a complicated process that is reg-
ulated by intron and exon sequences, SR (serine/arginine-
rich) proteins, and other non-SR splicing factors, for
example, heterogeneous nuclear ribonucleoproteins
(hnRNPs). Alternative splicing occurs when the introns of
a certain pre-mRNA are excised in more than one way,
producing structurally and functionally different proteins
from the same gene in different cells, or different develop-
mental stages. It is estimated that more than 60% of
human genes undergo alternative splicing, making the
cellular process an essential mechanism for generating
protein diversity [1-4]. Both constitutive and alternative
splicing play important roles in the regulation of gene
expression in eukaryotes [5]. A growing number of genetic
diseases have been found to be caused by alternative or
aberrant splicing events [6-9]. Mutations in cis-elements
for splicing are primarily responsible for these diseases.
However, tissue-specific splicing factors, such as those
identified in amyotrophic lateral sclerosis (ALS), are also
suggested to cause the aberrant pathogenic processing of
pre-mRNA [10-13]. In addition, polymorphisms and
from 8th International Conference on Alzheimer's Disease Drug Discovery
New York, NY, USA. 15–16 October 2007
Published: 3 December 2008
BMC Neuroscience 2008, 9(Suppl 2):S10 doi:10.1186/1471-2202-9-S2-S10
<supplement> <title> <p>Proceedings of the 8<sup>th </sup>International Conference on Alzheimer's Disease Drug Discovery</p> </title> <editor>Howard Fillit</editor> <sponsor> <note>The publication of this supplement was made possible by the generous support of the conference sponsors: Forest Laboratories, Inc.; Bellus Health Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Esai, Inc., Ortho-McNeil Neurologics, Inc.; Sanofi-Aventis US, Inc.; Schering-Plough; Accera, Inc.; Acumen Pharmaceuticals, Inc.; Pfizer Inc.; and Wyeth Research.</note> </sponsor> <note>Reviews</note> <url>http://www.biomedcentral.com/content/pdf/1471-2202-9-S2-info.pdf</url> </supplement>
This article is available from: http://www.biomedcentral.com/1471-2202/9/S2/S10
© 2008 Zhou et al; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
BMC Neuroscience 2008, 9(Suppl 2):S10 http://www.biomedcentral.com/1471-2202/9/S2/S10
Page 2 of 8
(page number not for citation purposes)
genetic background contribute to variation in alternative
splicing in specific genes, leading to modification of phe-
notypes in diseases (reviewed by Wang and Cooper [14]).
A typical exon is defined by its sequence, which is usually
less than 300 base pairs long and, together with its sur-
rounding introns, contains at least three core cis-elements:
a 5' splicing site, a 3' splicing site, and a branch point
[5,15]. The splicing events begin with recognition of these
elements by assembly of the spliceosome, a complex con-
sisting of different small nuclear ribonuclear particles
(snRNPs; U1, U2AF65, U4/U6, and U5), SR proteins
(SRP30C, SRP20, SRP40, SRP55, SC35, SF2, hTra2b1),
and other factors, including SF1 [5] (reviewed by Kramer
[15]). The 5' site is initially paired with U1 snRNP and
then replaced by U6 snRNP. The large subunit of splicing
factor U2AF binds to the polypyrimidine tract while SF1
interacts with the branch site [16]. SR proteins, on the
other hand, function as trans-splicing factors that facilitate
the interaction of U1 snRNP with the 5' splice site, and the
assembly of spliceosomes. through interactions with
U2AF [17], SF1, and other splicing factors. After a series of
conformational changes, introns are enzymatically
removed and exons are ligated at 5' and 3' splicing sites.
Exons, as well as introns, contain cis-regulatory splicing
elements that activate or inhibit the splicing of a specific
exon. These elements include splicing enhancers and
splicing silencers [18-21]. Due to the involvement of
many factors in the process of alternative splicing, one
would expect that any change of these elements in the
overall equation would tip the balance of exon inclusion/
exclusion.
The human tau gene is more than 100 kilobases long and
has been mapped to chromosome 17q21. It contains 16
exons, with the first exon (-1) as a part of the promoter
(Figure 1). Exons 4A, 6, and 8 are not present in the tau
mRNAs in human brain [22]. A full-length tau protein is
encoded by exons 1–13 and consists of 441 amino acids.
Three exons (exons 2, 3, and 10) undergo alternative
splicing, giving rise to six isoforms of tau (Figure 1). The
fetal tau isoform excludes exons 2, 3, and 10, while adults
express all six tau isoforms, which range from 352–441
amino acids in length, depending on inclusion or exclu-
sion of exons 2, 3, and 10 [23]. One of the major charac-
teristics of the tau protein is the presence of four carboxy-
terminal tandem repeat sequences (of 31 or 32 amino
acids), each of which is encoded by exons 9, 10, 11, and
12 [24-27]. Since exon 10, which encodes the second
repeat, is alternatively spliced., isoforms of tau are classi-
fied as either 3R taus (three repeats) or 4R taus (four
repeats) (Figure 1) [28].
Alternative splicing of exon 10 is developmentally regu-
lated. It has been shown that >95% of tau mRNA in fetal
brain excludes exon 10, while 40–50% of tau mRNAs in
The tau genomic structure and splicing productsFigure 1
The tau genomic structure and splicing products. The tau gene has 16 exons. Exons 4A, 6, and 8 are not expressed in the 
human brain. Exons 2, 3, and 10 are alternatively spliced, producing six different mRNAs. The mRNA with or without exon 10 
encodes a tau protein with four repeats (4R) or three repeats (3R), respectively. Adapted from Lee et al. [28].
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adult central nervous system includes this exon [29]. Exon
10 is relatively small at 93 base pairs. Exonic splicing
enhancers, as well as an exonic splicing silencer, have
been identified within this exon [29-31]. By analyzing
mini-genes constructed from exon 9, intron 9, exon 10,
intron 10 and exon 11 of the tau gene, we and others have
also shown that additional cis-elements, including exon 9,
exon 11, and trans-factors – for example, SRp20, SRp55,
SRp75, SRp30c, ASF, SC35 and hTra2β1 – regulate exon
10 splicing [29,32-34]. Studies of tau pre-mRNA identi-
fied a stem-loop structure at the exon 10-intron 10
boundary, the disruption of which alters exon 10 splicing
[30,35,36]. Several splicing factors, including hTra2β1,
SF2/ASF, SRp55, and SRp30C, affect exon 10 splicing by
directly binding to exonic enhancers [37,38]. However, it
is unclear how other cis-elements and trans-factors are
involved in exon 10 splicing.
Tau is abundantly expressed in the central nervous system,
predominantly located in axons, and expression is also
detectable in the axons of peripheral neurons. Only low
levels of expression are observed in central nervous system
astrocytes and oligodendrocytes [39-41]. The main func-
tion of tau is to bind and stabilize microtubules. The bind-
ing of tau to microtubules promotes their polymerization
[39,42]. Analysis of the tau sequence revealed that tau has
four microtubule-binding motifs that are located in four
repeat regions at the carboxyl terminus of the protein
within conserved 18 residue long binding elements sepa-
rated by less conserved spacers of 13–14 amino acids [28].
4R-tau isoforms, which contain an additional binding ele-
ment, have a greater affinity for microtubules and are
more efficient in promoting their polymerization than
3R-tau isoforms [43,44]. It is interesting that in adult
human brain, the ratio of 3R-tau to 4R-tau isoforms is
about 1 [43]. Therefore, one would expect that in a nor-
mal individual the ratio of 4R-tau/3R-tau proteins is bal-
anced.
Tauopathies and mutations in Tau
Tauopathies comprise a group of neurodegenerative dis-
orders that share a common pathological feature: the for-
mation of insoluble intraneuronal aggregates composed
of filamentous hyperphosphorylated tau proteins [28,45].
Paired helical filaments and the hyperphosphorylation of
tau are two of the most recognized molecular characteris-
tics in Alzheimer's disease (AD) and several other neuro-
degenerative tauopathies, for example, frontotemporal
dementia with Parkinsonism linked to chromosome 17
(FTDP-17) and progressive supranuclear palsy (PSP) [28].
The genetic relevance between tau and tauopathies came
from linkage analysis of FTDP-17 and other neurodegen-
erative diseases, many of which were mapped to the
region on chromosome 17q21–22 where the tau gene is
located [46-50]. Subsequently, mutations were identified
in the tau gene from FTDP-17 patients [48,51-53]. To
date, at least 35 distinct pathogenic mutations in the tau
gene that lead to the formation of filaments made of
hyperphosphorylated tau [54] have been described in a
large number of families with FTDP-17 (Table 1; http://
www.molgen.ua.ac.be/ftdmutations) [22,55]. Several
other mutations have also been described in PSP, Pick's
disease, and Parkinson's disease (Table 2; http://
www.molgen.ua.ac.be/ftdmutations) [56-60]. It has also
been demonstrated that the majority of missense muta-
tions that reside in coding regions of tau exons 9, 10, 12,
or 13 alter the ability of tau to interact with microtubules
and to promote microtubule assembly [51,52,59,61-63].
On the other hand, additional mutations (for example,
three silent mutations in exon 10, a deletion mutation,
seven substitutions of the intron following exon 10, and
one mutation in intron 9) disrupt exon 10 splicing cis-ele-
ments (Table 1). This mostly results in the increased pro-
duction of tau mRNA with exon 10 inclusion, shifting the
3R-tau/4R-tau ratio in favor of more 4R-tau [51,64-66]. It
has been also demonstrated that the exonic mutations
S305N, N279K, Δ280K, and N296H may not only alter
tau functions, but also affect splicing enhancers, or desta-
bilize the stem loop structure of tau pre-mRNA, causing
Table 1: Mutations in the tau gene that are identified in FTDP-17 patients
Exon or intron Mutations
EX1 Arg5His
EX9 Ile260Val; Leu266Val; Gly272Val
EX10 Asn279Lys; ΔK280; ΔK281; Asn296His; Pro301Thr; Pro301Ser; Pro301Leu; Gly303Val; Ser305Asn
EX11 Leu315Arg; Lys317Met; Ser320Phe
EX12 Gly335Ser; Gly335Val;Gln336Arg; Val363Ile; Val337Met; Glu342Val; Ser352Leu; Lys369Ile
EX13 Arg406Trp; Thr427Met
IVS9 -10G>T
EX10 Asn279Lys; ΔK280; Asn296; Leu284; Ser305, Asn296His; Pro301Thr
IVS10 +3G>A; +11T>C; +12C>T; +13A>G; +14C>T; +16C>T; +19C>G
Data are derived from http://www.molgen.ua.ac.be/ftdmutations. Mutations in bold affect exon 10 splicing. IVS, intervening sequence.
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abnormal exon 10 inclusion/exclusion [30,67]. All these
results suggest that aberrant exon 10 splicing is one of the
most important mechanisms in the pathogenesis of
tauopathies.
In addition to the mutations that have been identified in
FTDP-17 patients, it has been suggested that additional
pathogenic mutations or polymorphisms in introns that
affect exon 10 splicing may be present in tauopathies [28].
Analysis of tau protein and mRNA in PSP indicates that
more 4R-tau is produced in these patients [68]. However,
unlike other tauopathies, PSP has usually been considered
to be sporadic in nature. Conrad et al. [69], however, dem-
onstrated an association between a polymorphic dinucle-
otide repeat marker, (GT)n, found in intron 9 of the tau
gene and PSP. These results were subsequently confirmed
by several other groups [70,71]. Further studies indicate
that a series of polymorphisms within the tau gene (for
example, eight single nucleotide polymorphisms, one
deletion, and the (TG)n repeat) are inherited in com-
pleted linkage disequilibrium, defining the tau gene as
two extended haplotypes, H1 and H2 [72] (reviewed by
Schraen-Maschke et al. [22]). Importantly, it was found
that the most common allele (H1 haplotype) and geno-
type (H1/H1) were over-represented in PSP patients com-
pared with normal controls. However, although the
dinucleotide polymorphism is associated with extended
H1/H2 haplotypes in disequilibrium, it has been consid-
ered a variation that may not have biological significance
in the disease process. Taken together with the discoveries
of the over-production of 4R-tau, and disequilibrium
linkage to the tau gene in PSP patients, it is reasonable to
presume that variations in intron 9 or intron 10 could be
critical to influencing exon 10 inclusion/exclusion in
these patients [71,73-75].
In contrast, dysregulation of tau pre-mRNA splicing con-
tributing to AD pathogenesis is still under debate. Several
groups have shown by quantitative RT-PCR that there is
no direct correlation between the 4R/3R ratio and tau
pathology in AD patients [73-75]. On the other hand,
Glatz et al. [76] demonstrated that in the temporal cortex
of many AD brains, production of 4R-tau is significantly
elevated, suggesting the importance of exon 10 inclusion/
exclusion in the pathogenesis of AD. Nevertheless,
although mutations have only been identified in the tau
gene from FTDP-17 patients, tau polymorphisms, or other
factors that may affect tau splicing, appear to be genetic
risk factors for neurodegenerative diseases with tauopa-
thy, in particular in PSP and AD patients.
Pharmacological intervention of tau splicing in 
tauopathy
Tau is hyperphosphorylated and forms aggregates in
brains of tauopathic patients. One would expect that
small molecules and drugs that prevent these processes
could be identified and used as therapeutic treatments.
Not surprisingly, extensive efforts have been made to
identify these molecules to inhibit formation of tau fila-
ments or tau hyperphosphorylation as the mainstream
objective in the search for drugs for treatment of tauopa-
thies [55,77]. However, the overlooked exon 10 splicing
of the tau gene has been gaining ground during the past
few years as an area of study for potential treatment of
tauopathies.
Several well-documented technologies that target aberrant
splicing of specific genes in the treatment of diseases have
been discussed in a recent review by Gallo et al. [55].
Among them, antisense oligoribonucleotides have been
most commonly cited. For instance, Kalbfuss et al. [78]
demonstrated that oligoribonucleotides binding to E10
splicing junctions could suppress the predominant inclu-
sion of exon 10 in tau mRNA in rat PC12 cells. Other
examples of modulating alternative splicing with anti-
sense oligoribonucleotides include the genes SMN and
Bcl-x [21,79]. Another strategy that is often employed to
stimulate the inclusion or exclusion of a specific exon is to
use bifunctional oligoribonucleotides. These molecules
are made of an antisense sequence designed to bind to an
exonic element and a trans-factor sequence or peptide
domain mimicking a trans-splicing factor [80-82]. Rela-
tive to antisense oligonuribonucleotides or bifunctional
oligoribonucleotides, spliceosome-mediated RNA trans-
splicing (SMaRT) is new. SMaRT is a technology that was
developed based on the natural occurring trans-splicing
event between two independently transcribed pre-mRNAs
[83]. By taking advantage of this finding, Puttaraju et al.
[83] developed a series of RNA pre-trans-splicing mole-
cules capable of base-pairing to and trans-splicing with a
conventional target pre-mRNA. They demonstrated that
splicing of the conventional pre-mRNA was modified by
these RNA pre-trans-splicing molecules both in vitro and
in transfected cells. SMaRT has been tested in tau and
SMN and shown great promise in correcting abnormal
splicing of these two genes [83-85].
Table 2: Mutations in the tau gene that are identified in other 
tauopathies
Exon Mutation Disease
EX1 Arg5Leu PSP
EX9 Lys257Thr Pick
EX10 ΔN296 PSP
EX13 Gly389Arg (G>A mutation) Pick
EX13 Gly389Arg (G>C mutation) Pick
EX13 Gln424Lys Parkinson's disease
Data are derived from http://www.molgen.ua.ac.be/ftdmutations. PSP, 
progressive supranuclear palsy.
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However, one specific area Gallo et al. [55] did not discuss
in their review is whether small molecules or chemical
compounds can potentially be used to treat diseases by
targeting splicing defects. To provide proof-of-principle,
we used neurodegenerative spinal muscular atrophy
(SMA) as a model. SMA is caused by the homozygous loss
of the SMN1 gene. SMN2, which differs from SMN1 by a
single nucleotide within exon 7 that affects the efficiency
of its incorporation into the mRNA transcript, is preserved
in SMA patients [86,87]. Increased exon 7 insertion into
SMN2 mRNA has been suggested as a potentially effective
approach for SMA treatment [88]. Using a cell based assay
we have developed, we identified the phosphatase inhib-
itor sodium orthovanadate in a small screen of chemicals
known to affect signaling pathways [88]. Additional
screening of a library of compounds identified aclaru-
bicin, a chemotherapeutic anthracycline drug that is
related to adriamycin [89], and indoprofen, a common
non-steroidal anti-inflammatory drug (NSAID) [90].
Aclarubicin, but not adriamycin, increased the amount of
full-length transcript produced by the SMN2 gene, which
in turn restored SMN protein levels in fibroblasts isolated
from a SMA patient. In addition, we showed that aclaru-
bicin has no effects on the splicing of Bcl-x, tau and
Myosin V genes [89], indicating a relatively specific effect
of aclarubicin on the splicing of the SMN2 gene [89]. We
conclude from our studies of SMN that relative specific
small molecules able to reverse abnormal splicing may be
identified for disease treatment.
Conclusion
Aberrant inclusion of exon 10 into tau mRNA promotes
the increased production of 4R-tau and has been increas-
ingly recognized as one of the causes of tauopathies in
FTDP-17, PSP, and many AD patients [51,64-66,76]. The
similarity between exon 7 splicing in the SMN gene and
exon 10 splicing in the tau gene prompted us to design a
cell-based assay using luciferase as a reporter for the iden-
tification of small molecules that can reverse abnormal
exon 10 inclusion. The mini-reported genes are displayed
in Figure 2[91]. When exon 10 is excluded, the luciferase
is expressed, while inclusion of exon 10 shifts luciferase
out of the reading frame, resulting in no luciferase activity.
Compounds that stimulate luciferase activity would likely
act by reducing exon 10 inclusion in the tau mRNA. Based
on this assay, we have carried out low- and high-through-
put screening. While characterizing more than 500 com-
pounds that stimulated luciferase activity (T Zou et al.,
unpublished data), we speculate that it is not out of reach
that relative specific small molecules will be identified for
further development of drugs for treatment of tauopa-
thies.
List of abbreviations used
AD: Alzheimer's disease; ALS: amyotrophic lateral sclero-
sis; FTDP-17: frontotemporal dementia with Parkinson-
ism linked to chromosome 17; PSP: progressive
supranuclear palsy; SMA: spinal muscular atrophy;
SmaRT: spliceosome-mediated RNA trans-splicing;
snRNP: small nuclear ribonuclear particle.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
This article has been published as part of BMC Neuroscience Volume 9 Sup-
plement 2: 2008 Proceedings of the 8th International Conference on Alzhe-
imer's Disease Drug Discovery The full contents of the supplement are 
available online at http://www.biomedcentral.com/1471-2202/9?issue=S2.
Validation of a cell-based luciferase system for measurement of exon 10 spli ing in the tau gene (adapted f o  Yu et alFigure 2
Validation of a cell-based luciferase system for measurement 
of exon 10 splicing in the tau gene (adapted from Yu et al. 
[91]). (A) The luciferase mini-gene construct. The firefly luci-
ferase gene was fused downstream of exon 11 in frame with 
a SI9/LI10 mini-gene containing the M14 (G to T) mutation. A 
stop codon was introduced into exon 10 by mutagenizing 
position 73 in exon 10 (A to T). The nucleotide A of the ini-
tiation codon ATG in the luciferase gene was converted to T. 
(B) A control mini-gene with a fused Renilla luciferase to 
exon 11. (C) The firefly luciferase mini-gene (A) was co-
transfected into SKN-MC cells with constructs of SRp40, 
SRp20, or SRp55. Relative firefly luciferase activities were 
normalized using the Renilla luciferase control (B). (D) RT-
PCR from cells described in (C) was carried out to quantify 
exon 10 inclusion/exclusion.
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